In Sweden, glibenclamide has been found in wild fish in concentrations close to therapeutic concentrations in humans, which also is reasonable based on the substance solubility in fat and measured concentration in wastewater. Mechanism based efficacy data is lacking.
Glibenclamide is included in the Stockholm County Council's table of pharmaceuticals with a negative environmental impact according to the environmental programme 2017–2021.
Concrete proposals on how to work to reduce emissions of environmentally harmful pharmaceuticals on the list have been developed in close cooperation with the Stockholm Drug and Therapeutics Committee's expert advice. The action proposals were developed from an environmental perspective. The patient's best always goes first and several pharmaceuticals on the list are also included in the Wise list. However, for such pharmaceuticals, there may be measures that could reduce the environmental impact.
Concrete proposal for glibenclamide
The risk insignificant, according to Fass.se, is calculated on total sold amount (kg) of the substance in Sweden during the year 2015 and the toxicity of the substance, i.e. consideration has not been given to measured levels in the environment.
Author: Health and Medical Care Administration, Region Stockholm